REDWOOD CITY, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will participate in a fireside chat as part of the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3 at 9:50 a.m. ET. To listen to a live webcast of this event, or access an archived we ...

Core Insights - Revolution Medicines, Inc. is a late-stage clinical oncology company focused on developing targeted therapies for RAS-addicted cancers [3] - The company will report its financial results for Q1 2025 on May 7, 2025, after market close, followed by a webcast to discuss these results and corporate progress [1] Company Overview - Revolution Medicines is developing a pipeline of RAS(ON) inhibitors aimed at suppressing various oncogenic variants of RAS proteins [3] - Current clinical candidates include daraxonrasib (RMC-6236), elironrasib (RMC-6291), and zoldonrasib (RMC-9805), with RMC-5127 anticipated to be the next to enter clinical development [3] - The company is also exploring additional RAS(ON) mutant-selective inhibitors such as RMC-0708 (Q61H) and RMC-8839 (G13C) [3]